ADAM17 and breast cancer: Since our results of overexpression experiments for ADAM17 in MCF7 cells indicated the dose-dependency between ADAM17 expression and IFN-γ degradation, i.e., IFN-γ inactivation, our results may explain the correlation of tumor progression in breast cancer to the extent of ADAM17 expression29.